GlobeNewswire

CloudCraze Named a Visionary in Gartner Magic Quadrant for Digital Commerce

Dela

Cloud-based B2B commerce platform recognized for its completeness of vision and ability to execute

CHICAGO, May 03, 2017 (GLOBE NEWSWIRE) -- CloudCraze, an enterprise digital commerce solution built natively on Salesforce, has once again been named a Visionary in the 24 April 2017 Gartner Magic Quadrant for Digital Commerce.

"We believe it's an honor to be named a Visionary by Gartner for the second year in a row. For us, this recognition demonstrates that we are a disruptive force in the digital commerce market and are providing significant value for our customers through fast implementation and robust B2B functionalities," said Chris Dalton, CEO of CloudCraze. "We feel this reaffirms that our Salesforce-native cloud-based approach to digital commerce is exactly what B2B organizations need to be successful in the shift towards digital."

CloudCraze delivers robust B2B commerce built natively on Salesforce, the world's #1 CRM and most-trusted cloud platform. It enables native capabilities for incorporating Salesforce Sales Cloud and Service Cloud functionality into the digital commerce platform, providing a single view of the customer by sharing data and businesses processes across CRM and commerce systems. Centralized data empowers sales representatives with a clearer picture of customer needs and purchasing habits to cross-sell, upsell and personalize offerings more effectively.

CloudCraze provides strong B2B capabilities and faster site launches. Simplified implementation through an agile approach enables faster time-to-market, resulting in an earlier payback period for B2B organizations. Additionally, CloudCraze's depth of B2B functionality address the complex nature of the B2B commerce industry. The platform's B2B-specific capabilities include contract pricing for multiple contracts at once, order and pricing override functionality based on a person's role, and account-based viewing settings.

The Gartner Magic Quadrant for Digital Commerce analyzed 21 vendors on their completeness of vision and ability to execute. Vendors are assessed on market presence and company viability, product functionality and product agility. The vendors with the highest aggregated evaluation scores in the inclusion criteria are included in the report and placed on a market spectrum of leaders, challengers, visionaries and niche players.

"Over the past year, we've continued to expand our ability to deliver a customer-centric digital commerce solution as a Salesforce Platinum ISV Partner and through strategic partnerships with leaders in digital innovation, including Adobe and Deloitte Digital," Dalton furthered. "Our commitment to regular product enhancements, including our recent Spring '17 release, will ensure we're continuing to provide the fastest, most flexible B2B commerce platform on the market."

This announcement comes on the heels of CloudCraze's recognition in The Forrester Wave(TM): B2B Commerce Suites, Q1 2017. To learn more about CloudCraze's recently launched Spring '17 release and its new product, CloudCraze Exchange, click here.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About CloudCraze

CloudCraze delivers robust B2B commerce native on Salesforce. It allows businesses to generate online revenue fast and easily scale for growth. Its Customer-First Commerce model puts the customer at the core, informing every interaction with data across commerce, sales, marketing, service and more. With the trusted Salesforce infrastructure and core capabilities, CloudCraze provides infinite flexibility to extend functionality, add products and channels, and conduct billions of dollars in transactions anywhere. CloudCraze powers Customer-First Commerce for industry leaders such as AB InBev, Barry-Callebaut, Coca-Cola, Ecolab, GE, Kellogg's, L'Oreal, Symantec, and WABCO.

CloudCraze is funded by Insight Venture Partners and Salesforce Ventures.

CloudCraze is recognized in The Forrester Wave(TM): B2B Commerce Suites, Q1 2017 and as a Visionary in the Gartner Magic Quadrant for Digital Commerce 2017. CloudCraze is a Salesforce Platinum ISV Partner.

Media contacts
Rachel Gulden
Senior Account Executive
rachel.gulden@walkersands.com
312.267.0530

Sarah Traxler
Senior Director, Marketing
sarah.traxler@cloudcraze.com
312.752.4473 x1003



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CloudCraze via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company Pharmanest changes name and signs licensing agreement15.10.2018 13:25Pressmeddelande

STOCKHOLM, October 15, 2018. Karolinska Development's portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé Skin Health. Palette Life Sciences (former Pharmanest) has announced a licensing agreement with Nestlé Skin Health. The agreement gives Palette Life Sciences the worldwide commercialization and development rights for three products: Deflux®, Solesta® and BarrigelTM. The products are all based on the NASHATM (Non Animal Stabilized Hyaluronic Acid) technology. Palette Life Sciences will focus immediately on sales of Deflux and Solesta and will begin preparing for worldwide commercialization of Barrigel. Nestlé Skin Health will continue to manufacture the products on behalf of Palette Life Sciences. Palette Life Science will continue the development of SHACT under the name LidbreeTM. Lidbree will be submitted for European regulatory review later this year. Karolinska Development is a passive investo

Karolinska Development's portfolio company Pharmanest changes name and signs licensing agreement15.10.2018 13:25Pressmeddelande

STOCKHOLM, October 15, 2018. Karolinska Development's portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé Skin Health. Palette Life Sciences (former Pharmanest) has announced a licensing agreement with Nestlé Skin Health. The agreement gives Palette Life Sciences the worldwide commercialization and development rights for three products: Deflux®, Solesta® and BarrigelTM. The products are all based on the NASHATM (Non Animal Stabilized Hyaluronic Acid) technology. Palette Life Sciences will focus immediately on sales of Deflux and Solesta and will begin preparing for worldwide commercialization of Barrigel. Nestlé Skin Health will continue to manufacture the products on behalf of Palette Life Sciences. Palette Life Science will continue the development of SHACT under the name LidbreeTM. Lidbree will be submitted for European regulatory review later this year. Karolinska Development is a passive investo

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum